Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387620900> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4387620900 abstract "Objective: Clinical data suggests cardiovascular benefits from anti-diabetes drugs including SGLT-2 and DPP-4 inhibitors, but the mechanisms remain unclear. This study evaluates the effect of DPP-4 inhibitor sitagliptin and SGLT-2 inhibitor canagliflozin on myocardial fibrosis in a swine model for chronic myocardial ischemia. Methods: Twenty-one Yorkshire swine underwent ameroid constrictor placement on the left coronary circumflex to model chronic myocardial ischemia. Two weeks post-op, swine were assigned to one of three groups: control (CON, n=8), canagliflozin 300mg daily (CAN, n=8), or Sitagliptin 100mg daily (SIT, n=5). After 5 weeks of treatment, swine underwent terminal harvest and tissue collection. Fibrosis was quantified using Masson's trichrome. Immunoblotting was used to quantify protein expression. Results: Trichrome stain showed a significant decrease in perivascular and interstitial fibrosis in the CAN and SIT groups compared to CON (all p<0.05) but no difference between the SIT and CAN groups (Figure 1). Immunoblot showed a decrease in Jak2, pSTAT3 to STAT 3 Ratio, pSMAD 2/3, and SMAD 2/3 (all p<0.05) in the SIT group compared to CON, and decreased pSTAT3 to STAT 3 Ratio, pSMAD 2/3, and SMAD 2/3 (all p<0.05) in the CAN group compared to CON. Jak2 was decreased in the SIT compared to CAN group (p=0.04), and MMP-13 was decreased in the CAN compared to SIT group (p<0.001). Conclusions: Sitagliptin and canagliflozin result in a similar reduction in perivascular and interstitial fibrosis in a swine model for chronic myocardial ischemia. This reduction in fibrosis likely contributes to the improved cardiovascular outcomes seen with DPP-4 and SGLT-2 inhibitors." @default.
- W4387620900 created "2023-10-14" @default.
- W4387620900 creator A5001760558 @default.
- W4387620900 creator A5006261578 @default.
- W4387620900 creator A5012657061 @default.
- W4387620900 creator A5026287360 @default.
- W4387620900 creator A5033320609 @default.
- W4387620900 creator A5048145879 @default.
- W4387620900 creator A5088180214 @default.
- W4387620900 date "2023-08-04" @default.
- W4387620900 modified "2023-10-15" @default.
- W4387620900 title "Abstract P2149: Modulation Of Cardiac Fibrosis By SGLT-2 Inhibitor Canagliflozin And DPP-4 Inhibitor Sitagliptin In A Swine Model For Chronic Myocardial Ischemia: A Comparative Analysis" @default.
- W4387620900 doi "https://doi.org/10.1161/res.133.suppl_1.p2149" @default.
- W4387620900 hasPublicationYear "2023" @default.
- W4387620900 type Work @default.
- W4387620900 citedByCount "0" @default.
- W4387620900 crossrefType "journal-article" @default.
- W4387620900 hasAuthorship W4387620900A5001760558 @default.
- W4387620900 hasAuthorship W4387620900A5006261578 @default.
- W4387620900 hasAuthorship W4387620900A5012657061 @default.
- W4387620900 hasAuthorship W4387620900A5026287360 @default.
- W4387620900 hasAuthorship W4387620900A5033320609 @default.
- W4387620900 hasAuthorship W4387620900A5048145879 @default.
- W4387620900 hasAuthorship W4387620900A5088180214 @default.
- W4387620900 hasConcept C126322002 @default.
- W4387620900 hasConcept C134018914 @default.
- W4387620900 hasConcept C156490143 @default.
- W4387620900 hasConcept C163031210 @default.
- W4387620900 hasConcept C164705383 @default.
- W4387620900 hasConcept C204232928 @default.
- W4387620900 hasConcept C2777180221 @default.
- W4387620900 hasConcept C2777451236 @default.
- W4387620900 hasConcept C2778763485 @default.
- W4387620900 hasConcept C2779284873 @default.
- W4387620900 hasConcept C2780559512 @default.
- W4387620900 hasConcept C2910068830 @default.
- W4387620900 hasConcept C3018763269 @default.
- W4387620900 hasConcept C541997718 @default.
- W4387620900 hasConcept C555293320 @default.
- W4387620900 hasConcept C70983919 @default.
- W4387620900 hasConcept C71924100 @default.
- W4387620900 hasConcept C98274493 @default.
- W4387620900 hasConceptScore W4387620900C126322002 @default.
- W4387620900 hasConceptScore W4387620900C134018914 @default.
- W4387620900 hasConceptScore W4387620900C156490143 @default.
- W4387620900 hasConceptScore W4387620900C163031210 @default.
- W4387620900 hasConceptScore W4387620900C164705383 @default.
- W4387620900 hasConceptScore W4387620900C204232928 @default.
- W4387620900 hasConceptScore W4387620900C2777180221 @default.
- W4387620900 hasConceptScore W4387620900C2777451236 @default.
- W4387620900 hasConceptScore W4387620900C2778763485 @default.
- W4387620900 hasConceptScore W4387620900C2779284873 @default.
- W4387620900 hasConceptScore W4387620900C2780559512 @default.
- W4387620900 hasConceptScore W4387620900C2910068830 @default.
- W4387620900 hasConceptScore W4387620900C3018763269 @default.
- W4387620900 hasConceptScore W4387620900C541997718 @default.
- W4387620900 hasConceptScore W4387620900C555293320 @default.
- W4387620900 hasConceptScore W4387620900C70983919 @default.
- W4387620900 hasConceptScore W4387620900C71924100 @default.
- W4387620900 hasConceptScore W4387620900C98274493 @default.
- W4387620900 hasIssue "Suppl_1" @default.
- W4387620900 hasLocation W43876209001 @default.
- W4387620900 hasOpenAccess W4387620900 @default.
- W4387620900 hasPrimaryLocation W43876209001 @default.
- W4387620900 hasRelatedWork W2145610847 @default.
- W4387620900 hasRelatedWork W2469454309 @default.
- W4387620900 hasRelatedWork W2493655186 @default.
- W4387620900 hasRelatedWork W2518492470 @default.
- W4387620900 hasRelatedWork W3084585140 @default.
- W4387620900 hasRelatedWork W3115461287 @default.
- W4387620900 hasRelatedWork W3117942680 @default.
- W4387620900 hasRelatedWork W4243368715 @default.
- W4387620900 hasRelatedWork W4385306655 @default.
- W4387620900 hasRelatedWork W2029430168 @default.
- W4387620900 hasVolume "133" @default.
- W4387620900 isParatext "false" @default.
- W4387620900 isRetracted "false" @default.
- W4387620900 workType "article" @default.